VOLITIONRX LTD (VNRX) VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Devices
VolitionRX Ltd NYSE:VNRX Healthcare · Medical - Devices
Mkt Cap $6.81M
EV -
SI 3.9%
Net Cash/Sh -
CLOSED · Nov 17 -5.56%$0.1887 CLOSED · Nov 17 Prev close $0.1998 -5.56%Close $0.1887 -4.56%AH close $0.1801 VOL 3.08M $ Vol $597K RVOL 0.81x
Mkt Cap $6.81M
EV -
VOL 3.08M sh
$ Vol $597K
RVOL 0.81×
SI 3.9%
Net Cash/Sh -
Press Release
VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
VolitionRx published a 2026 progress review citing >95% early-stage cancer detection in a blinded 81-subject Capture-Seq cohort and peer-reviewed validation of Nu.Q® NETs for predicting sepsis mortality. Revenue grew 134% year-to-date to $3.0 million, while operating costs fell 13% and convertible note debt was cut by over $5.0 million to roughly $0.7 million.
• 17h ago AI analysis › Press Release
Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
VolitionRx expanded its supply agreement with Fujifilm Vet Systems in Japan to cover the Nu.Q® Vet Feline Test, extending the Nu.Q® technology to Japan's nearly nine million cats. The company expects the feline test to be the world's first simple, affordable blood-based liquid biopsy for feline cancer, with development to run on the IDS i10 automated analyzer platform.
• 1d ago AI analysis › Press Release
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
VolitionRx reported Q3 2026 revenue of approximately $1.6 million, up 157% year-over-year from $0.6 million, driven by increased recognition of deferred revenue. Losses narrowed materially: operating loss fell 35% to $3.3 million and net loss to $3.8 million, aided by 14% lower operating expenses and a 28% headcount reduction. The company also prepaid its $7.5 million convertible note in cash. Cash stands at only $2.4 million despite $5.2 million of ATM proceeds in the quarter, and the CEO took a further salary cut to 50% of original level while the board cut cash fees at least 50%, underlining funding pressure pending a substantial licensing deal.
• 5d ago AI analysis › Press Release
VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
VolitionRx will host its Q3 2026 earnings and business update conference call on Friday, November 13 at 8:30 a.m. U.S. Eastern Time. The call will be hosted by CEO Cameron Reynolds, CFO Terig Hughes, and Corporate Secretary Rodney Rootsaert, covering third-quarter events, subsequent developments, and upcoming milestones.
• 8d ago AI analysis › Press Release
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
VolitionRx signed a non-binding Letter of Intent with Denmark's Missionpharma A/S to explore development and worldwide launch of Volition's lateral flow prototype test for NETosis. The initial clinical focus is a finger-prick test for triaging neonatal sepsis in newborns and young infants, targeting low- and middle-income countries where sepsis is a major cause of newborn deaths. Missionpharma, which supplies UN agencies and health ministries and reaches over 100 million patients annually, could assist with low-cost manufacturing, clinical studies, and distribution.
• 21d ago AI analysis › Press Release
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
VolitionRx made a $500,000 cash partial prepayment on its senior secured convertible note with Lind Global Asset Management, cutting the remaining balance to $706,667 from an original $2.4 million. Under an accompanying waiver, Lind agreed not to exercise conversion rights before January 1, 2027 unless the stock closes at or above $0.275 per share, and monthly repayments for November and December 2026 were deferred.
• 21d ago AI analysis › Press Release
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx shared further details and video of the official launch of the DETECSEPS program in France, a government-funded consortium focused on early detection of sepsis in emergency-department patients with suspected infection. The project, a winner of the French Health Innovation Agency's 'Challenge Prevention' call operated by the Banque Publique d'Investissement under the France 2030 plan, carries €6.3 million (~$7.3 million) in government funding and will evaluate the strategy in 1,000 patients across AP-HP and Hospices Civils de Lyon emergency departments.
• 2mo ago AI analysis › Press Release
VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx's Nu.Q NETs assay has been selected as the sole biomarker for DETECSEPS, a €6.3 million (~$7.3 million) French government-funded consortium program for the early detection of sepsis, formally launched alongside IHU SEPSIS and AP-HP under the France 2030 plan. IDS France, part of Revvity, will measure Nu.Q NETs on its IDS i10 automated analyzer with results available within one hour, evaluating suspected-infection patients in the emergency departments of AP-HP's Bichat-Claude-Bernard and Ambroise Paré hospitals.
• 2mo ago AI analysis › Press Release
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
VolitionRx announced the full cash pre-payment of the outstanding balance on its $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC, more than eight months ahead of its May 20, 2027 maturity date. CEO Cameron Reynolds said prepaying the balance in cash prevents further potential dilution to stockholders associated with the note, and that further debt and expense reduction remains a top priority.
• 2mo ago AI analysis › Press Release
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
VolitionRx presented early-stage solid cancer detection data using its Capture-Seq™ technology in the main auditorium at the ESMO MAP conference in London, targeting a $36 billion TAM in early cancer detection and minimal residual disease. In initial cohorts the test reported no false positives, detecting 49/49 cancers in the first cohort including 23 early stage I/II cases alongside 21 healthy controls, and 13/14 later-stage cancers in a second blinded cohort with 10 additional healthy controls. A third blinded validation cohort of 81 subjects, 59 colorectal and lung cancer patients and 22 healthy controls, detected 95% of stage I and II cancers.
• 2mo ago AI analysis › Press Release
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx reported $1.4 million in H1 2026 revenue, a 112% increase year-over-year, and anticipates a $5 million milestone payment following the publication of its feline lymphoma clinical manuscript. The company also advanced its sepsis program with inclusion in a $7.3 million French government-backed study scheduled to start in September 2026. Clinical validation efforts yielded positive results, including a peer-reviewed paper demonstrating Capture-Seq detected over 95% of Stage I and II cancers in a validation cohort.
• 2mo ago AI analysis › Press Release
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
VolitionRx announced the publication of a peer-reviewed paper in Critical Care Medicine confirming its Nu.Q® NETs H3.1 biomarker as an independent predictor of 28-day mortality and renal replacement therapy needs in sepsis patients. The study found higher biomarker levels in septic shock and a clear dose-response relationship with acute kidney injury severity, suggesting utility for early risk stratification.
• 2mo ago AI analysis › Press Release
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
VolitionRx reported second quarter revenue of approximately $0.4 million, flat year-over-year, while first-half revenue grew 112% to $1.4 million. Operating expenses fell 32% in the quarter, driving a 34% reduction in operating loss to $4.2 million, as the company focuses on cost discipline.
• 3mo ago AI analysis › Press Release
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
VolitionRx reported that its lateral flow finger-prick prototype showed strong correlation with its established Nu.Q® NETs assay in sepsis patients, validating its utility for point-of-care testing. The study demonstrated a Spearman correlation of 0.85 and a Pearson correlation of 0.88 between the finger-prick sample and the standard lab assay, removing the dependency on centralized laboratories.
• 3mo ago AI analysis › Press Release
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
VolitionRx announced it will host a conference call on August 14 to discuss its second quarter 2026 financial results and provide a business update. CEO Cameron Reynolds, CFO Terig Hughes and CMO Louise Batchelor will host the session, which will cover recent milestones and upcoming events.
• 3mo ago AI analysis › Press Release
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
VolitionRx published the first peer-reviewed paper detailing its Capture-Seq™ liquid biopsy technology in the journal Clinical Epigenetics, demonstrating the isolation of >99% pure circulating tumor-derived DNA. Validation data reported 100% sensitivity in an initial cohort of 49 cancer patients with zero false positives, and a subsequent blinded validation cohort detected 95% of stage I and II cancers.
• 3mo ago AI analysis › Press Release
Volition Advances Nu.Q® NETs Platform Towards Commercialization
VolitionRx released a comprehensive update on its Nu.Q NETs platform, summarizing peer-reviewed clinical data that demonstrates the assay's ability to accurately distinguish sepsis from non-infectious inflammation and predict patient outcomes. The company highlighted a Total Addressable Market of approximately $3.8 billion on an annualized basis and confirmed it is in active discussions with several large diagnostic companies to accelerate development.
• 3mo ago AI analysis › Press Release
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
VolitionRx released data showing its Nu.Q Cancer Assay offers significant prognostic value for newly diagnosed lung cancer patients, enabling better risk stratification and treatment selection. The company completed clinical certification at Hospices Civils de Lyon and plans to submit a reimbursement dossier in France shortly, with a determination mandated within five months of admissibility.
• 4mo ago AI analysis › Press Release
VolitionRx Announces Collaboration with Sysmex
VolitionRx entered a collaboration with Sysmex to optimize its Nu.Q® NETs H3.1 assay on Sysmex's global in vitro diagnostics platform. The partnership leverages Sysmex's installed base and regulatory expertise to target diseases associated with NETosis, such as sepsis, where Volition believes its test can improve clinical decision-making.
• 5mo ago AI analysis › Press Release
VolitionRx Announces Pricing of $4.6 Million Public Offering
VolitionRx priced a public offering of 2.96 million shares and 1.48 million warrants at a combined price of $1.55 per share and half warrant. The deal generates approximately $4.6 million in gross proceeds, with an additional $2.3 million potential if warrants are fully exercised.
• 5mo ago AI analysis › Press Release ● Major
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
prnewswire.com • 5mo ago Press Release
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx reported Q1 2026 revenue of $1 million, representing a 300% year-over-year increase, signaling accelerating commercial adoption. The company submitted a manuscript for its Nu.Q Vet feline cancer test, which could unlock a $5 million milestone payment upon publication, and is actively discussing licensing deals with more than a dozen global diagnostic leaders.
• 5mo ago AI analysis › Press Release
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx reported Q1 2026 revenue of $1.0 million, a 400% increase year-over-year from $0.2 million, driven by early commercial activity and licensing discussions. The company raised approximately $7.3 million in total capital during the quarter, including $5.4 million from at-the-market equity sales, $1.9 million from a convertible note, and $1.0 million in non-dilutive grants from the Walloon Region.
• 6mo ago AI analysis › Press Release ● Major
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
prnewswire.com • 6mo ago Press Release
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
VolitionRx submitted a clinical manuscript for its Nu.Q Vet Feline test, reporting 86% detection of feline lymphomas with 97% specificity. Publication of the study is expected to unlock a $5 million milestone payment and validates the technology for a new species.
• 6mo ago AI analysis › Press Release
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
prnewswire.com • 6mo ago Press Release
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
VolitionRx received acceptance from the NYSE American for its plan to regain compliance with continued listing standards, granting the company until August 6, 2027 to cure the deficiency. The exchange had notified the company in February that it failed to meet equity requirements due to reported losses in recent fiscal years and was ineligible for market cap exemptions.
• 6mo ago AI analysis › Press Release ● Critical
Volition Launches rNuQ™ Webshop Broadening Product Range
prnewswire.com • 6mo ago Press Release ● Major
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
prnewswire.com • 7mo ago Press Release
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
prnewswire.com • 7mo ago Press Release
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
prnewswire.com • 7mo ago Press Release
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
prnewswire.com • 7mo ago Press Release
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
prnewswire.com • 7mo ago Press Release
Volition Announces Detection of Over 95% of Early-Stage Cancers
prnewswire.com • 7mo ago Press Release
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
prnewswire.com • 8mo ago Press Release
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
prnewswire.com • 8mo ago Press Release
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
prnewswire.com • 9mo ago Press Release
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
prnewswire.com • 9mo ago Press Release
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
prnewswire.com • 9mo ago Press Release
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
prnewswire.com • 9mo ago Press Release
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
prnewswire.com • 9mo ago Press Release
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
prnewswire.com • 9mo ago Press Release
Volition Sponsors Symposium at Veterinary Meeting and Expo
prnewswire.com • 10mo ago Press Release
VolitionRx Secures $2.0 Million in Funding
prnewswire.com • 10mo ago Press Release
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
prnewswire.com • 10mo ago Press Release
Volition Issues Business Review 2025
prnewswire.com • 11mo ago Press Release
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
prnewswire.com • 11mo ago Press Release
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
prnewswire.com • 11mo ago Press Release
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
prnewswire.com • 11mo ago Press Release
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
prnewswire.com • 11mo ago